prikaz prve stranice dokumenta Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
European Journal of Internal Medicine, 29 (2016); 98-103. https://doi.org/10.1016/j.ejim.2015.12.014
Mikolašević, Ivana; Zaputović, Luka; Zibar, Lada; Begić, Ivana; Žutelja, Marta; Klanac, Ana; Majurec, Iva; Šimundić, Tihana; Minažek, Marija; Orlić, Lidija

Cite this document

Mikolašević, I., Zaputović, L., Zibar, L., Begić, I., Žutelja, M., Klanac, A. ... Orlić, L. (2016). Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels. European Journal of Internal Medicine, 29., 98-103. doi: 10.1016/j.ejim.2015.12.014

Mikolašević, Ivana, et al. "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels." European Journal of Internal Medicine, vol. 29, 2016, pp. 98-103. https://doi.org/10.1016/j.ejim.2015.12.014

Mikolašević, Ivana, Luka Zaputović, Lada Zibar, Ivana Begić, Marta Žutelja, Ana Klanac, Iva Majurec, Tihana Šimundić, Marija Minažek and Lidija Orlić. "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels." European Journal of Internal Medicine 29 (2016): 98-103. https://doi.org/10.1016/j.ejim.2015.12.014

Mikolašević, I., et al. (2016) 'Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels', European Journal of Internal Medicine, 29, pp. 98-103. doi: 10.1016/j.ejim.2015.12.014

Mikolašević I, Zaputović L, Zibar L, Begić I, Žutelja M, Klanac A, and sur.. Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels. European Journal of Internal Medicine [Internet]. 2016 [cited 2024 December 06];29:98-103. doi: 10.1016/j.ejim.2015.12.014

I. Mikolašević, et al., "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels", European Journal of Internal Medicine, vol. 29, pp. 98-103, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:052725. [Accessed: 06 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
AuthorIvana Mikolašević
AuthorLuka Zaputović
AuthorLada Zibar
MBZ: 254864
AuthorIvana Begić
MBZ: 287874
AuthorMarta Žutelja
AuthorAna Klanac
AuthorIva Majurec
AuthorTihana Šimundić
AuthorMarija Minažek
AuthorLidija Orlić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We have analyzed effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on evolution of hemoglobin (Hb) and hematocrit (Htc) levels as well as on the evaluation of kidney graft function in stable renal transplant recipients (RTRs) in respect with initially higher or lower Hb and Htc values. The study group comprised of 270 RTRs with stable graft function. Beside other prescribed antihypertensive therapy, 169 of them have been taking RAAS inhibitors We wanted to analyze the effect of the use of RAAS inhibitors on Hb and Htc in patients with initially higher or lower Hb/Htc values. For this analysis, only RTRs that were taking RAAS inhibitors were stratified into two groups: one with higher Hb and Htc (initial Hb ≥150 g/L and Htc ≥ 45%) and another one with lower Hb and Htc (initial Hb<150 g/L and Htc < 45%) values. Thirty-four RTRs with initially higher Hb and 41 RTRs with initially higher Htc had a statistically significant decrease in Hb (p=0.006) and Htc (p<0.0001) levels after 12-months of follow up. In the group of patients with initially lower Hb (135 RTRs) and Htc (128 RTRs) there was a significant increase in Hb (p=0.0001) and Htc (p=0.004) levels through the observed period. The use of RAAS inhibitors has been associated with a trend of slowing renal insufficiency in RTRs (p=0.03). RAAS inhibitors lower Hb and Htc only in RTRs with initially higher levels. In patients with initially lower Hb and Htc levels, the use of these drugs is followed by beneficial impact on erythropoiesis and kidney graft function.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEuropean Journal of Internal Medicine
Numberingvol. 29, pp. 98-103
p-ISSN0953-6205
DOIhttps://doi.org/10.1016/j.ejim.2015.12.014
URN:NBNurn:nbn:hr:184:052725
Publication2016
Document URLhttp://bib.irb.hr/790599
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2022-03-08 12:34:55